Article Text

Download PDFPDF
Neurointervention: a call to science
  1. Matthew J Gounis
  1. Correspondence to Dr Matthew J Gounis, Department of Radiology, New England Center for Stroke Research, University of Massachusetts Medical School, 01655, Worcester, Massachusetts, USA; matthew.gounis{at}umassmed.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The long history of the field of neurointerventional surgery1 2 entered its modern period with the development of the detachable coil.3 Since that time, the explosion of medical device and imaging technologies has led to profound improvements in clinical outcomes of patients with cerebrovascular disease.4–13 The recent landmark trials of mechanical thrombectomy in stroke represent perhaps the most impressive treatment effect in modern medical interventions. Much of this effort was funded by the private sector. Ironically, the first publication of modern stent-retriever thrombectomy was described as a little-known result of a National Institute of Biomedical Imaging and Bioengineering-funded project.14 However, the impressive innovations and accomplishments in neurointerventional surgery have been achieved primarily with collaborations between physician-scientists and industry to develop techniques and devices to treat cerebrovascular disease through a minimally invasive approach.

Today I entered ‘endovascular’ and ‘stroke’ to the NIH reporter query that returned 14 projects. Given the impact of stroke on our healthcare system coupled with the impressive patient outcomes of intra-arterial …

View Full Text

Footnotes

  • Contributors MJG solely responsible for the content.

  • Competing interests MJG has been a consultant on a fee-per-hour basis for Codman Neurovascular, InNeuroCo, Medtronic Neurovascular and Stryker Neurovascular; holds stock in InNeuroCo; and has received research support from the National Institutes of Health (NIH), Anaconda, CereVasc LLC, Codman Neurovascular, Gentuity, Microvention, Medtronic Neurovascular, Neuravi, Philips Healthcare, InNeuroCo, R92M, Rapid Medical, The Stroke Project, Stryker Neurovascular, and the Wyss Institute.

  • Provenance and peer review Commissioned; internally peer reviewed.